SEC EDGAR · Company announcement
INM: Company disclosure
Filed 8-K for an event or period dated 2026-11-03. Company disclosure.
Follow INM- Became public
- Nov 3, 2026, 4:47 PM EST
- Event / period date
- Nov 3, 2026
- Collected
- Nov 16, 2026, 7:07 AM EST
Why this is connected
This filing identifies InMed Pharmaceuticals Inc. as the issuer of the security. The company's SEC identifier connects it to INM.
News release, dated November 03, 2026 ↗Source evidence
Read the source excerpt or record
Item 7.01 Regulation FD Disclosure. On November 3, 2026, the Company reported financial results for the first quarter of the fiscal year 2027 which ended September 30, 2026. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated November 03, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: November 3, 2026 By: /s/ Eric A Adams Eric A Adams President & CEO
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.